



Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting

March 3, 2025

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Mar. 3, 2025-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting taking place March 12-14, 2025, in San Diego, C.A.

Details of the poster presentation are as follows:

Abstract Title: ADI-270, an Armored Allogeneic Anti-CD70 $\gamma\delta$ CAR T Cell Therapy, Demonstrates Improved Efficacy and Safety in Preclinical Models Compared to Conventional $\alpha\beta$ CAR Benchmarks

Poster/Abstract Number: 39

Presenting Author: Shon Green, Ph.D.

Date/Time: Wednesday, March 12, 2025, from 5:10 p.m. – 6:45 p.m. PT

Abstract Title: A Phase 1/2 First in Human Study of ADI-270, an Armored Allogeneic Anti-CD70 Chimeric Antigen Receptor $\gamma\delta$ T Cell Therapy, in Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)

Poster/Abstract Number: 136

Presenting Author: Gregory Vosganian, M.D.

Date/Time: Thursday, March 13, 2025, from 5:00 p.m. – 6:30 p.m. PT

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250303266774/en/): <https://www.businesswire.com/news/home/20250303266774/en/>

Adicet Bio, Inc.

Investor and Media Contacts

Investors:

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Precision AQ

212-362-1200

janhavi.mohite@precisionaq.com

Media:

Kerry Beth Daly

kbdaly@adicetbio.com

Source: Adicet Bio, Inc.